Cerebrolysin 5ml injections for memory disorders, dementia (1 blister x 5 tubes x 5ml)

Dosage form Box of 1 blister x 5 tubes x 5ml
Specifications Peptid Cerebrolysin Concentrate, Sodium Hydroxide, Peptide essence
Ingredient Intelligence due to brain vessels, Alzheimer, traumatic brain injury

Ingredient

Composition information	Content
Peptid Cerebrolysin Concentrate	215.2mg
Sodium hydroxide	2.1mg
Peptide essence

Uses

Indications

Cerebrolysin are indicated in the following cases:

Memory disorders, concentration disorders.

Degenerative degeneration, including Alzheimer's disease.

Intelligence due to vascular disease, multi -seat infarction.

Set of complex intelligence (both degeneration and blood vessels).

Stroke (ischemia and bleeding).

After trauma and surgery, after shock, stamping and after neurosurgery.

Pharmacy

The effect of Cerebrolysin has been proven through some clinical and clinical tests. Cerebrolysin is essentially a brain peptide that has a very specific neurological effect, affecting the brain and central nervous system according to many mechanisms. Cerebrolysin's versatile action mechanism is explained as follows:

Enhancing and improving metabolism of nerve cells, thus preventing lactic acid infection in brain oxygen or anemia.

Adjustment of neuromable synap, thereby improving behavior and learning ability.

Effectively nerve nutrition, including increased neuronal differentiation, ensuring nerve function and protecting brain cells from lesions caused by anemia and poisoning.

Controlled clinical trials that Cerebrolysin improves the knowledge and mood of Alzheimer patients, thus reducing the number of patients who need care. Synthesis of patients improved clinical condition is 61.7% of all patients treated with Cerebrolysin (evaluated based on CGV standard: Clinical Global Impression).

Another clinical trial in patients with dementia due to brain vascular disease shows improvement in memory in patients treated with Cerebrolysin. It is also found that there is an improvement in general clinical image in this group of patients.

Another study in patients with 9 different neuropathy has confirmed the effectiveness of Cerebrolysin through the use of 11 different psychological trials for analysis. Patients with stroke or traumatic brain injury treated with Cerebrolysin also lead to rapid increase in recovery. Many documents on the treatment effect of Cerebrolysin have been published.

pharmacokinetics

Cerebrolysin is a product that contains low molecular peptides and some amino acids, produced from pure pure protein in pig brain by biotechnology, based on controlled standard -cutting enzymes. Evaluation of pharmacokinetics, the response of that product is very complicated because there is similarity with other endogenous peptides.

Therefore, Cerebrolysin's pharmacokinetics evaluate only limited in distribution. Cerebrolysin is marked with 1251 radioactive substance to monitor the distribution of this drug on the brain. In addition, the evaluation of the energy also added the results of the studies on the above distribution of this drug:

Use Sprague Dawley rats by Frey and Frey methods. Use 125 | Mark the DPEPTID of Cerebrolysin. The mouse's tail intravenous injection (n = 8) is 0.75mg on average (110.9 microlit) and 35.24 micrcoci of the Cerebrolysin mixture marked and not marked. After 33 minutes, transmitting 0.9% NaCl solution and 4% Paraformaldehyde, testing the components of the mouse brain. Quantifying Cerebrolysin concentrations in brain tissue and other tissues in the range of 170 - 390 Nanogram Cerebrolysin/Gram tissue. The result is as follows:

Cerebrolysin concentration of tissues:

tissue

Cerebrolysin/Model

781

1,143

655

1,024

920

1,282

774

1,707

32,159

The neurotrophic effect of Cerebrolysin can be identified in plasma after this injection 24 hours.

Preciper clinical In-Vivo experiments also show that similar results on the central nervous system are injected into the brain as well as injecting into peripheral veins, which is also an indirect evidence of the overcoming blood-brain barrier of this drug.

Before taking Cerebrolysin 5ml injections for memory disorders, dementia (1 blister x 5 tubes x 5ml)

How to use

drugs used for injection.

Dosage

Cerebrolysin dose up to 5ml can be intramuscularly. Larger than 5ml can be intravenous or transmitted. Cerebrolysin can be mixed in standard solution (physiological saline, Ringer solution, 5%glucose, dextran 40) and slowly transmitted for at least 20 - 60 minutes.

Cerebrolysin inject once a day and within 10-20 days. That is considered a treatment.

In mild cases, 1 - 5ml can be used, in case of 10 - 30ml weighing, the length of the treatment time and the dose depends on the age of the patient and the severity of the disease. Usually the treatment lasts 3 or 4 weeks. The treatment can be repeated several times and it depends on the clinical response of the patient. Between treatments, should take medicine.

In severe cases, it is not advisable to stop the drug suddenly, but should continue treatment by injecting the drug once a day and every 2 days, for 4 weeks. From the above clinical trials, the dose instruction for adults is suggested as follows:

Intellectual decline: dose from 5 - 30ml/24 hours.

After a bloody stroke or traumatic brain injury 10 - 60ml/24 hours.

What to do when overdose?

What to do when forgetting 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Cerebrolysin 5ml contraindications in the following cases:

Sensitive to the ingredients of the drug.

Correct epilepsy or epilepsy, or epilepsy with increasing epilepsy frequency.

Severe kidney failure.

Precautions when using

Patients with severe kidney failure should not use Cerebrolysin.

The ability to drive and operate machinery

Clinical trials about Cerebrolysin show that this drug does not affect the ability to drive and operate machinery.

Pregnancy and lactation

Experiments on animals do not see any evidence of teratogenic effects. Because there is no clinical data on using Cerebrolysin in pregnant patients, Cerebrolysin does not use breastfeeding, except for the case of effective expected efficiency, which is greater than the ability to cause harm.

Medicinal interaction

Using Cerebrolysin along with antidepressants or Mao inhibitors can cause increased accumulation of drugs. In that case, the dose should be reduced.

Storage

Store safe, away from children.

Keep in a dry place, the temperature does not exceed 30 ° C, avoiding light.

Keep medicine in carton packaging.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.